Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
DFFN - Diffusion Pharmaceuticals Inc
-0.04(-3.42%)9:00:00 PM 1/15/2021
Diffusion Pharmaceuticals Inc is a publicly traded biotechnology and drug development company based in Charlottesville, Virginia, U.S. It was co-founded in 2001 by American life sciences entrepreneur David Kalergis and University of Virginia Chemical Engineering Professor John L. Gainer. Gainer is the inventor of the company’s platform technology of oxygen diffusion-enhancing compounds and its lead drug, trans sodium crocetinate . TSC acts to increase the rate at which oxygen moves through blood plasma by the process of diffusion, a phenomenon that forms the basis for the company's name. On January 8, 2016, the formerly privately-held company merged with Restorgenex Cororation to become a publicly-traded NASDAQ-listed company with the trading symbol DFFN. TSC and other oxygen diffusion-enhancing compounds, including bipolar trans carotenoid salts , have been investigated by Diffusion Pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues . Most recently, Diffusion has begun the initiation of clinical trials in the U.S. and Eastern Europe for the use of trans sodium crocetinate in the treatment of COVID-19 patients suffering from respiratory distress-related oxygen deficiency and the risk of multiple organ failure. Gainer invented the concept of oxygen diffusion-enhancing compounds and its specific embodiment, TSC, while a Professor of Chemical Engineering at the University of Virginia. He secured the first patent on the molecule and its uses in 2000. Before TSC's invention, he and colleagues conducted research on the effects of oxygen diffusion-enhancing compounds in various animal disease models, including atherosclerosis, arthritis and cancer. At that time, crocetin, a naturally occurring carotenoid compound, was the focus of their research. With the invention of TSC, their research turned to the potential use of this synthetic oxygen diffusion-enhancing compound for the improved treatment of hemorrhagic shock on the battlefield. This research, which was supported financially by the United States Office of Naval Research , was conducted in Gainer’s University of Virginia laboratory. Following the company's formation by Kalergis and Gainer in 2001, both ONR and private funding was obtained, enabling company researchers to set up their own laboratory and, along with collaborators, perform further preclinical studies into uses of TSC in the treatment of hemorrhagic shock and other hypoxic conditions, such as ischemic stroke, central nervous system disorders, and cancer.
Stock Chart


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Stock news

    Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

    CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows: Event:H.C. Wainwright BioConnect 2021 Conference Date: January 11-14, 2021 Registration: The recorded presentation can be accessed by conference par...

    DFFN: Planning for Additional Studies of TSC…

    By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Update on COVID-19 Trial Diffusion Pharmaceuticals (NASDAQ:DFFN) is currently conducting the 100-303 COVID trial of trans sodium crocetinate (TSC) in hospitalized COVID-19 patients in Romania ( NCT04573322 ). This is primarily a safety and tolerability study of TSC when it is administered four times a day for up to

    Is Diffusion Pharmaceuticals Inc. (DFFN) A Good Stock To Buy?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

    Insider Buys Diffusion Pharmaceuticals Shares

    Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) rose by 4.1% from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, November 18 showed that & Secretary Elder William Robert bought 10,000 shares at $0.67 on Monday, Nov 16, and bought 5,000 shares at $0.63 on Tuesday, Nov 17.The transaction moved the executive's stake in Diffusion Pharmaceuticals Inc. to 10,000 shares.The Importance of Insider Transactions Insider transactions shouldn't be used primarily to make an...

    Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

    Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 PatientsAnnounces Next Steps in Development Program for Lead Product CandidateEnded Quarter with $21.9 million in Cash and Cash EquivalentsCHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”) today reported financial results for the three and nine months ended September 30, 2020 and provided certain updates on its development program ...

    Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

    CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusion’s Chief Executive Officer. Dr. Galloway is board certified in Emergency Medicine and will assume responsibility of leading the Company’s product development efforts, including clinical trial...

    Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

    CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the position of general counsel and corporate secretary, effective immediately. He will report to Robert Cobuzzi, Ph.D., chief executive officer of Diffusion. As general counsel, Mr. Elder is responsible for overseeing all legal functions, in particular corporate governance, securities and compliance and c...

    DFFN: First Patients Dosed in COVID-19 Trial…

    By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update First Patients Dosed in COVID-19 Trial On September 10, 2020, Diffusion Pharmacueticals, Inc. (NASDAQ:DFFN) announced that the first two patients have been dosed in the open-label Phase 1b clinical trial of trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. The trial is taking place at the Romanian

    We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Can Afford To Drive Business Growth

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...